The role of insulin glulisine to improve glycemic control in children with diabetes mellitus

Diabetes, Metabolic Syndrome and Obesity

Volumn 3, Issue , 2010, Pages 403-412

  Lih, Anna ^a,b   Hibbert, Emily ^a,b   Wong, Tang ^a,b   Girgis, Christian M ^a,b   Garg, Nidhi ^a,b   Carter, John N ^a,b  

^a ANZAC Research Institute   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Glulisine; Pediatrics; Type 1 diabetes mellitus

Indexed keywords

EID: 84949116250     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSOTT.S5116     Document Type: Review

References (42)

1. Danne T, Lange K, Kordonouri O. New developments in the treatment of type 1 diabetes in children. Arch Dis Child. 2007;92(11):1015–1019.
2. The effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr. 1994;125(2):177–188.
3. White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane W V. Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Benefcial effects of intensive therapy of diabetes during adolescence outcomes after the conclusion of the Diabetes Control and Complications Trial. J Pediatr. 2001;139(6):804–812.
4. Dahl-Jorgensen KLJ, Hanssen K F. Atherosclerosis in childhood and adolescents type 1 diabetes: early disease, early treatment? Diabetologia. 2005;48(8):1445–1453.
5. Siebenhofer A, Plank J, Berghold A, et al. Short acting inuslin analogs versus regular human insulin in pateints with daibetes mellitus. Cochrane Database Syst Rev. 2004;2:CD003287.
6. Holcombe JH, Zalani S, Arora VK, Mast CJ. Comparison of insulin lis-pro with regular human insulin for the treatment of type 1 in adolescents. Clin Ther. 2002;24(4):629–638.
7. sanof-aventis. Insulin glulisine(Apidra®). EU summary of product characteristics. Availalble from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/apidra/H-557-PI-en.pdf. Accessed 2010 Nov 5.
8. sanof-aventis. Insulin Glulisine (Apidra®) US prescribing information. Available from: http://products.sanof-aventis.us/apidra/apidra.pdf. Accessed 2010 Nov 5.
9. Dailey G, Rosenstock J, Moses R, et al. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care. 2005;37(11):702–707.
10. Rayman G, Profozic V, Middle M. Insuline glulisine imparts effective glycaemic control in patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76(2):304–312.
11. Lankisch M, Ferlinz K, Leahy J, Scherbaum WA, et al. Introducing a simplifed approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regiments of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab. 2008;10(12):1178–1185.
12. National Institutes of Health. Clinical Trials. Available from: http://www.clinicaltrials.gov/. Accessed 2010 Nov 5.
13. Apidra TM. Aventis Pharmaceuticals, Inc. Insulin glulisine (rDNA origin) injection. Available from: http://www.acessdata.fda.gov/drugsatfda_docs/label/2008/021629s015 lbll.pdf. Accessed 2010 Nov 5.
14. sanofi-aventis. Apidra prescribing information. Available from: http://products.sanof-aventis.us/apidra/apidra.pdf. Accessd 2009 Nov 5.
15. Heise T, Heinemann L. Rapid and long-acting insulin analogues as an aproach to improve insulin therapy: an evidence-based medicine assessment. Curr Pharm Dis. 2001;7(14):1303–1325.
16. Poulsen C, Langkjær L, Worsøe C. Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2007;7(1):142–150.
17. Sluzky VTJ, Klibanov AM, Langer R. Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc Natl Acad Sci U S A. 1991;88(21):9377–9381.
18. Brange J, editor. Galenics of Insulin: The Physico-chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations. Berlin, Germany: Springer-Verlag; 1987.
19. Richards J P, Stickelmeyer M, Flora DB, Chance RE, Frank BH, DeFelippis MR. Self association properties of monomeric insulin analogs under formulation conditions. Pharm Res. 1998;15(9):1434–1441.
20. Zoete V, Meuwly M, Karplus M. Study of the insulin dimerization: binding free energy calculation and per-residue free energy decomposition. Proteins. 2005;61(1):79–93.
21. Hennige AM, Strack V, Metzinger E, Seipke G, Häring HU, Kellerer M. Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors. Diabetologica. 2005;48(9): 1891–1897.
22. Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K. Pharmacokinetics, prandial glucose control, and safety of insulin glu-lisine in children and adolescents with type 1 diabetes. Diabetes Care. 2005; 28(9):2100–2105.
23. Garnock-Jones K P, Plosker GL. Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs. 2009;69(8): 1035–1057.
24. Garg S, Kelly WC. Insulin glargine and glulisine SoloSTAR pens for the treatment of diabetes. Expert Rev Med Devices. 2008;5(2): 113–123.
25. Philotheou A, Arslenian S, Blatnicky L, Peterkova V, Souhami E, Danne T. Efficacy and safety of insulin glulisine versus insulin lispro as part of a basal bolus regimen in children and adolescents with type 1 diabetes. Diabetologica. 2008;51(Supp 1:32):Abstract 950.
26. Hoogma R P, Schumicki D. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res. 2006;38(6):429–433.
27. Cobry E, McFann K, Messer L, et al. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther. 2010;12(3):173–177.
28. Garg SK, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract. 2005;11(1):11–17. [Erratum in Endocr Pract. 2005;11(2):145].
29. Kawamori R, Kadowaki T, Ishii H, et al. Efficacy and safety of insulin glulisne in japanese patients with type 1 diabetes mellitus; using glargine as basal insulin [Abstract Number 2074-PO]. Diabetes. 2008; 57 Suppl 1:A573.
30. Dreyer M, Prager R, Robinson A, et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res. 2005; 37(11):702–707.
31. Senstius J, Poulsen C, Hvass A. Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps. Diabetes Technol Ther. 2007;9:517–521.
32. sanofi-aventis. Apidra prescibing information. Available from: http://products.sanofi-aventis.us/apidra/apidra.html. Accessed 2009 Nov 4.
33. Stammberger I, Seipke G, Bartels T. Insulin glulisine – a comprehensive preclinical evaluation. Int J Toxicol. 2006;25(1):25–33.
34. Powers S W, Byars KC, Mitchell MJ, Patton SR, Standiford DA, Dolan LM. Parent report of mealtime behavior and parenting stress in young children with type 1 diabetes and in healthy control subjects. Diabetes Care. 2002;25(2):313–318.
35. Rave K, Klein O, Frick AD, Becker RH. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care. 2006;29(8):1812–1817.
36. Kotsanos JG, Vignati L, Huster W, et al. Health-related quality-of-life results from multinational clinical trials of insulin lispro: Assessing benefts of a new diabetes therapy. Diabetes Care. 1997;20(6): 948–958.
37. Home PD, Lindholm A, Riis A. European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med. 2000;17(11):762–770.
38. Bott S, Tusek C, Heinemann L, Friberg HH, Heise T. The pharmacokinetic and pharmacodynamic properties of biphasic insulin aspart 70 (BIAsp 70) are signifcantly different from those of biphasic insulin Aspart 30 (BIAsp 30). Exp Clin Endocrinol Diabetes. 2005;113(9): 545–550.
39. Kamoi K, Miyakoshi M, Maruyama R. A quality-of-life assessment of intensive insulin therapy using insulin lispro switched from short-acting insulin and measured by an ITR-QOL questionnaire: a prospective comparison of multiple daily insulin injections and continuous subcutaneous insulin infusion. Diabetes Res Clin Pract. 2004;64(1): 19–25.
40. Grey M, Boland E, Tamborlane W V. Use of lispro insulin and quality of life in adolescents on intensive therapy. Diabetes Educator. 1999;25(6): 934–941.
41. Deja GJ-CP, Muchacka-Bianga M, et al. Insulin lispro in treatment of children and adolescents with type 1 diabetes and its effect on quality of life. Diabetologia Polska. 2002;9(2):52–56.
42. Urakami T, Kawamaru T, Sugihara S, et al; Japanese Study Group of Insulin Therapy for Childhood and Adolescent Diabetes. A questionnaire survey on the use of quick-acting insulin analog in Japanese children and adolescents with type 1 diabetes. Pediatr Int. 2004;46(3):285–290.